
All branded drugs not facing generic, biosimilar competition must abide by MFN order in 'all markets,' HHS tells pharma
President Donald Trump put the biopharma industry on its back foot earlier this month with his executive order on international reference prices. While many unknowns remained at the time of the May 12 signing ceremony, his administration is now filling in …